Clinical Trial Update: Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating durvalumab as maintenance therapy after chemoradiation for unresectable esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Tiago Biachi | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN